Literature DB >> 26629268

Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629268      PMCID： PMC4665055     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

1.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 2.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

3.  Cost of illness and economic burden of chronic lymphocytic leukemia.

Authors:  Carl Rudolf Blankart; Taika Koch; Roland Linder; Frank Verheyen; Jonas Schreyögg; Tom Stargardt
Journal:  Orphanet J Rare Dis       Date:  2013-02-20       Impact factor: 4.123
  3 in total
  1 in total

1.  Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.

Authors:  Yanhua Zhou; Hongtao Lu; Meifeng Yang; Chenhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.